Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...

A new drug developed at UC Davis Health could provide a safer and more effective option for bladder cancer patients, reducing chemotherapy toxicity and potentially limiting the need for bladder ...

Kyverna’s investigational CAR-T therapy, mivocabtagene autoleucel (miv-cel) showed clinically meaningful mobility improvements in most stiff-person syndrome patients, prompting the company to plan an ...

The novel radiotracer ¹⁸F-FAPI-RGD in PET/CT scans shows potential for diagnosing ILD in connective tissue disease patients by highlighting fibroblast activation and tissue remodeling. Patients with ...

In visually impaired older adults, broken flooring, such as torn carpet, had the greatest fall risk at a 47% increase, followed by tripping hazards, like unsecured throw rugs or electrical cords, at ...

Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...

The future of dermatology is no longer just skin deep. This year’s American Academy of Dermatology (AAD) annual meeting was held March 7-11, 2025, in Orlando, FL, and it showcased the specialty’s ...

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

A new influenza strain could fuel a severe flu season while a surge in measles cases threatens U.S. elimination status, ...

Expiration of enhanced ACA subsidies in 2026 could lead to a 114% premium increase, affecting millions of Americans. Republican proposals include association health plans and health savings accounts, ...

A new scale for grading ocular adverse events in oncology trials addresses ambiguities in CTCAE version 5 and includes dose modification recommendations. The scale, implemented in the I-SPY 2 trial, ...

HSDD affects 40%-55% of postmenopausal women, often due to hormonal changes, impacting sexual desire and quality of life.